Early Botulinum Toxin for Muscle Stiffness Reduction in First-Time Stroke Patients: Improving Recovery and Independence

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

January 28, 2025

Primary Completion Date

February 1, 2027

Study Completion Date

February 1, 2030

Conditions
SpasticityStrokeNeurological Rehabilitation
Interventions
DRUG

Botulinum Toxin Type A (BoNT-A)

This intervention involves the early administration of botulinum toxin type A (BoNT-A) within the first 12 weeks after a cerebrovascular event. The injections target muscles affected by spasticity, aiming to reduce abnormal tone, prevent contractures, and improve functional mobility. BoNT-A works by blocking acetylcholine release at the neuromuscular junction, resulting in muscle relaxation. Ultrasound guidance or anatomical landmarks will be used for accurate injection. This early intervention capitalizes on the neuroplastic window and is combined with standard rehabilitation to enhance motor recovery and prevent long-term complications.

Trial Locations (1)

97155

"Hospital General Regional No.1 Lic. Ignacio García Téllez IMSS, Calle 41 101, Fénix, 97155 Mérida, Yuc.", Mérida

All Listed Sponsors
lead

Instituto Mexicano del Seguro Social

OTHER_GOV